000830:SZSELuxi Chemical Group Co., Ltd. Analysis
Data as of 2026-03-07 - not real-time
CN¥20.21
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Luxi Chemical is trading in a clear bullish technical zone, with the 20‑day SMA (18.30) sitting above the 50‑day (17.81) and 200‑day (13.98) averages, and a bullish MACD histogram (+0.13) supporting upside momentum. Momentum indicators remain firm as RSI sits at 62, suggesting the stock is approaching overbought levels while still having room to run toward the 20‑day resistance of 20.98. Fundamentally, the company faces pressure: revenue fell 4.8% year‑over‑year, profit margins are thin (≈5%), and the debt‑to‑equity ratio is high at 62, though cash flow remains positive and the dividend payout ratio is a modest 45% with a 1.73% yield. Valuation appears stretched, with a trailing P/E of 26.2 versus analyst mean target price of 18.53, indicating the market may be pricing in optimistic expectations. High 30‑day volatility (≈67%) and a modest beta (~0.55) add to short‑term price swings, while the stable, high trading volume reduces liquidity concerns.
Overall, the stock’s technical strength is offset by weakening top‑line growth, elevated leverage, and a valuation gap, making it a cautious hold with a tilt toward downside risk if earnings do not improve.
Overall, the stock’s technical strength is offset by weakening top‑line growth, elevated leverage, and a valuation gap, making it a cautious hold with a tilt toward downside risk if earnings do not improve.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish SMA crossover and MACD signal
- RSI approaching overbought territory
- Price near technical resistance
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Negative revenue growth and thin profit margins
- High debt‑to‑equity ratio
- Valuation above analyst target prices
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Sustained earnings pressure and modest free cash flow
- Elevated leverage limiting financial flexibility
- Overvalued multiples relative to peers and growth outlook
Key Metrics & Analysis
Financial Health
Revenue Growth-4.80%
Profit Margin4.91%
P/E Ratio26.2
ROE7.88%
ROA3.58%
Debt/Equity62.01
P/B Ratio2.0
Op. Cash FlowCN¥4.4B
Free Cash FlowCN¥100.0M
Technical Analysis
TrendBullish
RSI62.0
SupportCN¥16.63
ResistanceCN¥20.98
MA 20CN¥18.30
MA 50CN¥17.81
MA 200CN¥13.98
MACDBullish
VolumeStable
Fear & Greed Index68.77
Valuation
Target PriceCN¥18.53
Upside/Downside-8.30%
GradeOvervalued
TypeValue
Dividend Yield1.73%
Risk Assessment
Beta0.01
Volatility67.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.